Abstract
Sudden cardiac death (SCD) remains a major cause of mortality, and despite our knowledge of the causative genetic, molecular and biochemical cellular mechanisms involved, effective therapeutic strategies are lacking. Perturbations in cardiac Ca2+ handling promote arrhythmias and there is enormous interest in developing new anti-arrhythmics aimed at correcting Ca2+ release dysfunction. In particular, abnormal Ca2+ release arising as a result of acquired or genetic defects in cardiac ryanodine receptors (RyR2) has emerged as an important arrhythmogenic trigger in heart failure, and in a devastating genetic arrhythmia syndrome termed catecholaminergic polymorphic ventricular tachycardia (CPVT). Here, we evaluate how experimental insights into RyR2 structure-function are unravelling the precise molecular basis of channel dysfunction and are advancing the development of new therapeutic strategies. We also discuss the functional role of RyR2 in the context of the exquisite synergism existing between numerous cellular components involved in cardiac Ca2+ signalling, and how these complex interactions may be used to design new anti-arrhythmic approaches that target multiple facets of RyR2 regulation.
Keywords: Ryanodine receptor, calcium release channel, calcium signalling, arrhythmia, sudden cardiac death, arrhythmogenesis, excitation-contraction coupling, cardiac muscle
Current Pharmaceutical Design
Title: Developing New Anti-Arrhythmics: Clues from the Molecular Basis of Cardiac Ryanodine Receptor (RyR2) Ca2+-Release Channel Dysfunction
Volume: 13 Issue: 31
Author(s): Christopher H. George and F. Anthony Lai
Affiliation:
Keywords: Ryanodine receptor, calcium release channel, calcium signalling, arrhythmia, sudden cardiac death, arrhythmogenesis, excitation-contraction coupling, cardiac muscle
Abstract: Sudden cardiac death (SCD) remains a major cause of mortality, and despite our knowledge of the causative genetic, molecular and biochemical cellular mechanisms involved, effective therapeutic strategies are lacking. Perturbations in cardiac Ca2+ handling promote arrhythmias and there is enormous interest in developing new anti-arrhythmics aimed at correcting Ca2+ release dysfunction. In particular, abnormal Ca2+ release arising as a result of acquired or genetic defects in cardiac ryanodine receptors (RyR2) has emerged as an important arrhythmogenic trigger in heart failure, and in a devastating genetic arrhythmia syndrome termed catecholaminergic polymorphic ventricular tachycardia (CPVT). Here, we evaluate how experimental insights into RyR2 structure-function are unravelling the precise molecular basis of channel dysfunction and are advancing the development of new therapeutic strategies. We also discuss the functional role of RyR2 in the context of the exquisite synergism existing between numerous cellular components involved in cardiac Ca2+ signalling, and how these complex interactions may be used to design new anti-arrhythmic approaches that target multiple facets of RyR2 regulation.
Export Options
About this article
Cite this article as:
George H. Christopher and Lai Anthony F., Developing New Anti-Arrhythmics: Clues from the Molecular Basis of Cardiac Ryanodine Receptor (RyR2) Ca2+-Release Channel Dysfunction, Current Pharmaceutical Design 2007; 13 (31) . https://dx.doi.org/10.2174/138161207782341259
DOI https://dx.doi.org/10.2174/138161207782341259 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanofibers Based Tissue Engineering and Drug Delivery Approaches for Myocardial Regeneration
Current Pharmaceutical Design c-Myc and Downstream Targets in the Pathogenesis and Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Cytostatic Properties of Some Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type I Receptor Antagonists
Current Pharmaceutical Design Expression, Purification and Characterization of Recombinant Canine FGF21 in Escherichia coli
Protein & Peptide Letters Targeting Redox Signaling in the Vascular Wall: From Basic Science to Clinical Practice
Current Pharmaceutical Design Biochemical and Histochemical Comparison of Cholinesterases in Normal and Alzheimer Brain Tissues
Current Alzheimer Research Cross-Talk Between the Androgen Receptor and the Phosphatidylinositol 3-Kinase/Akt Pathway in Prostate Cancer
Current Cancer Drug Targets The Anti-Oxidant Properties of Isothiocyanates: A Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Myocardial Infarction after Rituximab Treatment for Rheumatoid Arthritis: Is there a Link?
Current Pharmaceutical Design Recent Advances in the Development of Selective CB2 Agonists as Promising Anti-Inflammatory Agents
Current Medicinal Chemistry Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Strategies for the Management of Acute Decompensated Heart Failure
Current Cardiology Reviews Obesity, Diabetes and Atrial Fibrillation; Epidemiology, Mechanisms and Interventions
Current Cardiology Reviews Editorial (Thematic Issue: Recent Advances in Management of Myocarditis)
Current Pharmaceutical Design The Role of Protease-Activated Receptors for the Development of Myocarditis: Possible Therapeutic Implications
Current Pharmaceutical Design The Meaning of Different Forms of Structural Myocardial Injury, Immune Response and Timing of Infarct Necrosis and Cardiac Repair
Current Vascular Pharmacology Pharmacological Modulations of the Renin-Angiotensin-Aldosterone System in Human Congestive Heart Failure: Effects on Peripheral Vascular Endothelial Function
Current Vascular Pharmacology Oxidative Stress and Endothelial Dysfunction: Say NO to Cigarette Smoking!
Current Pharmaceutical Design Editorial (Thematic Issue: Myokines and Exercise Training: More Shadows than Lights)
Current Pharmaceutical Design Mechanisms Involved in Metformin Action in the Treatment of Polycystic Ovary Syndrome
Current Pharmaceutical Design